Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 280 No 7500 p532
3 May 2008

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Melatonin tops list of unlicensed products imported into the UK

Melatonin treatments to tackle jet lag and sleep disturbance top the list of the most popular imported unlicensed products to the UK, according to statistics released by the Medicines and Healthcare products Regulatory Agency. Other lifestyle treatments that dominate the list include allergy patches, which are ranked sixth, followed by vitamin and topical supplements.

The recent controversy around the safety of the measles, mumps and rubella vaccination programme also impacts on the list, the report says. Monocomponent mumps vaccines are the eighth most popular imported unlicensed product.

Homoeopathy also features in the summary report for imported unlicensed medicines between October and December 2007, with demand for Abnoba vascum (mistletoe), which is used as supplementary therapy in the treatment of cancer patients, putting this product in 10th place.

The list of the top 50 imported unlicensed drugs follows a request for information under the Freedom of Information Act. The statistics and the report have been compiled and published as the MHRA continues its informal consultation on specials manufacturing — making unlicensed medicines to order — which finishes on 30 June 2008 (PJ, 8 March 2008, p266).

The report reveals that in the last quarter of 2007, 77 different licence holders notified the MHRA about their desire to import unlicensed drugs into the UK with 80 per cent of the notifications coming from just 10 per cent of the licence holders.

The report points out: “There appears to be an underlying trend for increase in the number of notifications received, although this has been masked by a decline in the number of notifications from the dominant importers.”

The MHRA believes compiling and releasing the information may benefit the present consultation and it is considering releasing quarterly statistics routinely if the present information is found to be useful.

Back to Top


©The Pharmaceutical Journal